Why Long-Term Oxygen Therapy Needs a Scientific Reset
In this episode of Lung Health Champion, host Tralisa Willis speaks with Dr. Joao de Andrade, Dr. Sanjay Sethi, and Susan Jacobs about long-term oxygen therapy (LTOT) and its place in respiratory research and clinical practice. The panel examines why much of the evidence supporting LTOT is decades old, where important research gaps remain, and how inconsistent prescribing, limited reassessment, equipment burdens, and access to high-flow oxygen can affect care. They also discuss the need for better education, improved delivery technology, clearer measures of benefit, national data collection, and an individualized approach that aligns oxygen therapy with each person’s goals and needs.
Key Points From This Episode
- Why LTOT receives less scientific attention than newer therapies
- Research gaps beyond chronic resting hypoxemia
- Treating oxygen as a prescribed drug rather than supportive equipment
- Differences between qualifying for oxygen and benefiting from it
- The need for consistent definitions and assessment of hypoxemia
- The importance of reassessing oxygen after hospitalization
- How early follow-up can identify equipment and adherence problems
- The role of nurses, respiratory therapists, and other clinical team members
- Gaps in clinician education about oxygen devices and delivery methods
- Matching oxygen equipment to individual needs and daily activities
- The burden, stigma, and mobility challenges associated with oxygen equipment
- Limitations of current portable and high-flow oxygen options
- The reduced availability of liquid oxygen
- Why delivery systems can influence research outcomes and adherence
- The need for better measures of oxygen therapy benefit
- Opportunities for biomarkers, registries, and pragmatic research
- Using electronic medical records and emerging technology to support research
- The potential for auto-titrating and improved oxygen delivery systems
- Setting expectations before beginning oxygen therapy
- Aligning treatment decisions with individual goals and quality of life
This episode is proudly supported by Inogen. Learn more.
- Dr. Joao de Andrade on LinkedIn:
https://www.linkedin.com/in/joao-de-andrade-379530153/ - Learn more about Dr. Joao de Andrade:
https://medicine.vumc.org/department-directory/Joao-de-Andrade - Learn more about Sanjay Sethi:
https://medicine.buffalo.edu/faculty/profile.html?ubit=ssethi - COPD Foundation:
https://www.copdfoundation.org - Production and editing by The Podcast Consultant:
https://thepodcastconsultant.com - Sign up for COPD Foundation's Newsletter:
https://www.copdfoundation.org/About-Us/Who-We-Are/Contact-Us.aspx#enewsletter
The podcast is provided by the COPD Foundation as an educational resource only and should not be considered as offering medical advice. This information should not be used as a substitute for a physician's professional judgment in providing advice, diagnosis, or treatment for any medical or health condition. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment before undertaking a new health care regimen. Do not disregard professional medical advice or delay in seeking it because of something you have heard on this podcast.
[Joao de Andrade] (0:00 - 0:13)
You find extremely diverse answers of how these things are measured in your clinical practice, and that is a barrier to research. If we don't collectively agree of how to diagnose a problem, we have a problem.
[Dr. Sanjay Sethi] (0:13 - 0:24)
There are people out there who are hospitalized, of course, needed the oxygen post-hospitalization. Now, the eight or 12 weeks out, they're supposed to get re-evaluated. I think you've seen numbers that happens less than half the time.
[Susan Jacobs] (0:24 - 0:36)
And I think managing expectations from the front can really improve compliance, like you mentioned, what are your goals for this therapy, what should they expect from this therapy, and that you're going to reevaluate them in a few months.
[Tralisa Willis] (0:43 - 2:14)
Welcome to the Lung Health Champion podcast, brought to you by the COPD Foundation. Each episode brings practical tips, expert insights, and a powerful lived experience. Today's episode is a part of our Unobstructed series that focuses on technical insights from trusted healthcare practitioners.
If you have lungs, you belong here. So let's take a deep breath together and get started. I'm your host, Tralisa Willis, and in this episode, we're discussing supplemental oxygen and its representation in scientific conversations.
Long-term oxygen therapy is the necessary treatment for hypoexamic patients, many of whom have chronic lung conditions. However, scientific discussions around the treatment are far fewer than other treatment options in comparison. We're going to explore why long-term oxygen therapy has received less attention than its counterparts, and the implications for clinical practice in patient-centered care.
We're joined today by Doctors Joao de Andrade and Sanjay Sethi, and by a long time Stanford University research nurse manager, Susan Jacobs. Welcome, and thank you all for taking the time to share your experience with us. Okay, so let's get started.
I want to start with you, Dr. Andrade. Many respiratory clinicians believe that long-term oxygen therapy, or LTOT, has lost its scientific visibility. Do you share this view?
And if so, can you share with us why?
[Joao de Andrade] (2:14 - 3:13)
It depends what you call scientific visibility, right? If you're talking about the fact that we haven't had a robust pipeline of clinical trials on oxygen therapy in this population, then the answer is, yeah, I agree. I think there are several layers to that.
One, oxygen therapy, as we know, has been set up based on evidence that came out of the early clinical trials in the early 1980s. So I think that we are talking about clinical trials that are 40 years plus old. So it's almost like the community thinks that perhaps this is set practice, and there are no questions that need to be answered.
There's, I think, one side of it. And I think there's a second aspect, which is clinical research in oxygen therapy is very costly. And I think there is perhaps less of an appetite from funding sources to support that kind of research.
The research needs to, I think, address the questions that remain in long-term oxygen therapy.
[Tralisa Willis] (3:13 - 3:15)
Dr. Sethi, would you like to add anything?
[Dr. Sanjay Sethi] (3:16 - 4:06)
Yeah, I tend to agree. I mean, you know, since those early trials, there was another trial, the lot one which looked at patients with moderate hypoxemia, and that was a third, I would say, significant trial. But there are so many unanswered questions still.
Yes, we have a well-defined population of patients who are persistently hypoxemic who benefit with oxygen in the context of COPD. But beyond that, here, there are a lot of other questions which I think need to be answered. It's not a drug, so there's not really an interest from pharmaceutical companies to sponsor their kind of research.
So most of the sponsorship for this research has to come from, you know, from our federal funding agencies. And considering the cost of it and the considering the number of people in it, I think we should be paying more attention to it.
[Tralisa Willis] (4:06 - 4:32)
So then, you know, Dr. Andrade and Dr. Sethi just spoke to the longevity of, you know, the research from 40 years ago, you know, that has continued until this day, as far as what we know with LTLT. Despite it being a cornerstone intervention for appropriately selected patients with chronic hypoxemia, LTLT receives relatively little discussion. What factors have contributed to this discrepancy?
[Susan Jacobs] (4:33 - 6:14)
There is relatively little scientific discussion, but I can guarantee you, if you call clinics across the nation, there's a lot of discussion, you know, ordering oxygen is a very labor-intensive endeavor, you know, ordering testing, setting it up, delivering it, training the patient, et cetera. So that's a huge discussion at the clinician level. I do think that ordering oxygen has become kind of a common task that's just done, but I would argue that I think there's more awareness now that these discussions around the patient with chronic resting hypoxemia is pretty well accepted.
I think we're hearing new discussions more around the benefit and evidence that's available on patients who only desaturate with exertion or isolated exertional hypoxemia. So that's where we lack the evidence, and I think there's more awareness about these differences in discussion and actually in some studies now. We underappreciated the burden that the patient undergoes, the stigma, you know, for some it's like the beginning of the end, and the data about outcomes and how we measure benefit is that, you know, number of steps for day, activity level, mobility are measuring echo, PA pressure, preventing right-heart strain, and then the burden socially and actually physically carrying these things around.
So I think the discussion around this is better now than it was a few years ago, because we're more aware that each patient's different, and that these exertional hypoxemic population, that bucket of patients, is where we need more evidence and more discussion. I think we're starting to see that.
[Joao de Andrade] (6:14 - 7:04)
There's the assumption that all patients with hypoxemia are the same, and they're not. The COPD patients, ILD patients, pulmonary hypertension, but they all have very unique needs. I don't think the scientific community has agreed on, you know, that there is evidence in the more recent clinical trials around survival, but is that the right way to design a clinical trial?
Patients, they value many, many other things about their daily lives that go beyond that. So I think as a community we need to work very hard on determining what are those outcome measures, and then create an infrastructure, a different way to think about how to study oxygen therapy so we can move the field forward.
[Susan Jacobs] (7:04 - 7:28)
Oxygen is ordered through a durable medical equipment company. It's the same company delivering walkers, wheelchairs, et cetera. And I think in the public's eye, and maybe the scientific community, it demotes oxygen, which is a critically, you know, physician-prescribed therapy, does how much, when, why.
And so it's setting makes it, I think, the perception is all sort of, I think, a bit.
[Dr. Sanjay Sethi] (7:28 - 8:09)
I would add just a couple more things. One is fine to have the, initially for resting hypoxymic patients, mortality was a good outcome. You know, nobody can argue with that, but you write the expectations that this therapy would, we need to change our outcomes when you look at different populations.
And I would also argue that we're not doing it right. We're not really assessing if the oxygen is actually working. If it's achieving the endpoints in terms of, you know, getting rid of the hypox, especially exertional hypoxymia.
So we need to revisit all that. And, you know, there's been good advances on how to deliver it that hasn't even caught up in the research and the implications of the better delivery systems in terms of outcomes. That also needs to be examined.
[Tralisa Willis] (8:09 - 8:36)
I do want to extend that just a little bit, and I'm going to go to you, Dr. Sethi. We've talked about how LTLT is definitely seen, you know, it's an established treatment. To the shared, you know, the community, the discussion may not be there scientifically the way we want, but it is there amongst clinicians.
Because it's attracting less scientific curiosity compared to new therapies, or can you explain why maybe it is not having the same amount of attention as new therapies?
[Dr. Sanjay Sethi] (8:37 - 9:20)
Part of it could be, again, the positive of funding, for example, is there enough interest from the federal funding agencies? Because the other primary ones we're going to rely on is enough interest from them in questions related to oxygen therapy. So I think that's one aspect of it.
And the second aspect, I think, is also the, you know, we need to really reframe the questions and reframe how we answer them. So there has to be enough of, I think, the society within our investigators and our societies, there has to be a drive. Let's come back to this and really put our energies in reframing it and then trying to answer those questions.
[Tralisa Willis] (9:20 - 9:46)
We have established that many clinicians perceive that long-term oxygen therapy is receiving less attention than other necessary therapies. Let's explore the reasons behind this discrepancy and why the discussion may have diminished over time. I'm going to go back to you, Dr. Andrade. Do you think LTLT suffers from a perception problem, where maybe it is considered supportive care rather than active therapeutic intervention?
[Joao de Andrade] (9:47 - 11:02)
Yeah, I agree. I think Susan made a very important point. And I'm going to emphasize that oxygen has been now relegated to the same basket as a walker
And we need to reframe it. Oxygen is a drug and is prescribed by a practitioner and has a certain dosing. So you need to determine what population that drug benefits and what those and when and what are the potential side effects.
So we need to really rethink the way we think oxygen and bring it back to where it belongs. As a chemical that has pharmacological action in the body and has its own side effects. So I think we can do that, but it will take change in the entire chain that deals with oxygen therapy all the way from, let's have more research to understand who benefits what are the potential side effects.
Let's devise better delivery systems that we have now. Do we need to fully correct hypoxemia or is this something that just gives patient comfort? Either way, it is a valid outcome measure, right?
But we need to study it.
[Tralisa Willis] (11:02 - 11:12)
Dr. Sethi, is the relative lack of new clinical trial data in LTOT one reason it receives less attention amongst healthcare professionals?
[Dr. Sanjay Sethi] (11:12 - 11:41)
Absolutely. You know, that is, there's not enough conversations about it, discussions about it. I mean, we just had a trial published on an interstitial lung disease, the PFOC trial, which was, you know, after a long time we had a trial that was being discussed in a major respiratory journal.
Otherwise, you need to go back quite some ways. So this is an issue that we need more publications, but to get more publications, we need more research. And to get more research, we need more support.
[Tralisa Willis] (11:41 - 11:51)
And so then, the current clinical practice guidelines provide sufficient practical guidance on patient selection, monitoring, adherence, and reassessment of LTOT.
[Susan Jacobs] (11:52 - 15:06)
So the current guidelines that we have that were published, in 2020. So, of course, that's six years. So they already need updating, but those guidelines do provide some very baseline guidance.
So we know that there were pretty strong recommendations for the use of oxygen with the patient, whose hypoxymic at rest, and that was with COPD and with ILD, interstitial lung disease. And then we know that also that these guidelines had, you know, suggested very much, you know, down strength and recommendations for use of oxygen with exertional hypoxymia. Those were isolated exertional.
So those are the same. And I think that's why we're reevaluating that that wasn't a strong recommendation, because we did not have data on testing patients who only desaturate with exertion for their outcomes. But other parts of the guideline include the recommendation for liquid oxygen.
So we know that there's a subset of patients that have very high flow needs, often with pulmonary fibrosis, that cannot use a portable device and leave their house, because we are basically back, I want to say almost 20 years, of not having liquid as a portable option that allows patients with that flow of, you know, a continuous flow of four to six liters or more. No portable device except a 15 or 18 pound e-tank provides their, you know, provides an adequate oxygen for them. The guidelines also strongly recommended for training and education.
It's hard to believe we had to put that in the guideline, but we felt we had to, because of the very frequent report that patients receive, call it dropshipping at their doorstep, not trained, and some will just send it back. It's too noisy. It's too heavy.
I don't know how to use it or using it appropriately. So those were in the guidelines and safety training. So those are critical, but, you know, we have areas that need evidence.
And one, we've already touched on the exertional hypoxemia. I think we also need to know that, like Dr. Adendrade mentioned, patients are different. If your patient hits 88% at minute five or six of a walk, are they the same as a patient that hits 80% at minute two?
You know, they both qualify for exertional oxygen. Neither of them desaturated rest, but they're different. And the machine that delivers to them is different and the training is different.
So we've really seen much better awareness of the equipment burden. And I think the guidelines, you know, touch on gaps in research, which are the patients that benefit? How can we predict which patient benefits?
What are those predictors? So I think the guidelines have a certain body of evidence that's pretty stable, but a mother body, which we need a lot of added information. And that's really the patient who has isolated exertional hypoxemia.
Although one could argue that studies done 40 years ago on COPD patients with resting hypoxemia might need repeating. But as has been mentioned, survival studies just aren't feasible. I don't think at this point.
[Joao de Andrade] (15:06 - 15:37)
I would put a call to arms to organizations like the COPD Foundation. No, we know there is actually data showing that implementation of guidelines lags behind sometimes many, many years and a lot of clinical practice in the United States often deviates from published guidelines. So we depend on organizations like you to help disseminate the guidelines that are produced by us, the scientific community.
So we really appreciate the partnership. Absolutely.
[Tralisa Willis] (15:37 - 16:09)
We all have our part to play and we want to do our part. So now that we have understanding why LTOT has lost visibility is very important, but perhaps even more important is what it means in day-to-day patient care. So let's talk a little bit about the impact on clinical practice.
Dr. Sethi, is there variability in how LTOT is prescribed across different regions or healthcare systems and could increase scientific discussion help address this issue?
[Dr. Sanjay Sethi] (16:09 - 17:05)
I would love to see publications on how well are the guidelines being used. You know, we have that you're done it for like goal guidelines and what I can't recall the paper, which is really looked at current prescribing practices. Do they confirm and I suspect they don't.
I mean, there's some things we have to do, but do they fully assess the effect of the consumer, for example, on their oxygen saturations? Are we just doing a simple ambulatory oximetry where they walk 60 meters or should we be doing this experiment at walk test to really assess are we addressing an insertion hypoxemia completely? You know, especially even in those patients with resting hypoxemia.
So, and then, you know, are we doing? So I think all of those need to come in need to be examined. I think that if you look at it carefully, there's going to be a lot of guideline variability in terms of application, which I think is a disservice to our patients.
[Joao de Andrade] (17:06 - 17:40)
And often, that was in the details, right? I think the definition of what is hypoxemia and how you measure, how you determine it. I think if you pull several pulmonologists or respiratory physicians, you find extremely diverse answers of how these things are measured in your clinical practice.
And that is a barrier to research, right? So if we don't collectively agree of how to diagnose a problem, we have a problem to advance the field forward. So we need to take care of those basic measures before we can advance the field.
[Tralisa Willis] (17:40 - 17:44)
And how do you guys feel that this affects the quality of life of the patient?
[Joao de Andrade] (17:44 - 19:14)
Put yourself in someone's shoes where they just receive the news that they have a chronic illness, likely progressive, that will likely shorten their lives. And now they're giving a therapy that, to Susan's point, is often perceived as the beginning of the end. There's a lot of uncertainty.
And then they have the equipment delivered to them. They don't no longer remember what they were told in clinic. So they often do what the driver of that's delivering oxygen told them to do.
And 99 out of 100 times when you bring the patient back to clinic, well, what we tell them to do and what they actually doing is a complete disconnect, right? So I think those are the barriers. And so the patient has a lot of uncertainty.
There's a lot of education that's needed that often is very difficult to do in the clinical practice at the pace that now we're all subjected to in terms of benchmarks and how many patients you have to see. Now, as an academic practice, we have the luxury of time, but I think in a community that may not be the case. So we need to rethink the way oxygen therapy is dealt with.
Just think about anti-quagulation, right? It became so unwieldy that we had to establish dedicated clinics to deal with anti-quagulation, because it was causing birth. It was doing in a way that was haphazard.
I think maybe a similar model needs to be thought about for oxygen therapy.
[Dr. Sanjay Sethi] (19:15 - 20:29)
I've actually mostly spoken about, there's a lot to discuss here, but I mostly spoken about underutilization of oxygen and appropriate. There's also overutilization. So I used to look at, run our, you know, be the physician representative for our home oxygen committee.
And we started talking about how many people don't get adequate follow-ups at eight weeks. And that's within the VA system, which is actually somewhat better, but in the community. So there are people out there who are hospitalized, of course, needed the oxygen post-hospitalization.
Now, the eight or 12 weeks out, they're supposed to get re-evaluated. I think you've seen numbers that happens less than half the time. And then they come to you and they, you know, just stay on oxygen.
And then they come to you an year or two later. Finally, they get referred and they'll say, oh, your oxygen level is 96% today. Let's take you for a walk.
And there's no de-saturation also. So everything's resolved and they had unnecessary life, you know, because it is a therapy, which has got, as was mentioned, positives and negatives. And then, so I think we need to be also cognizant of unnecessary prolonged therapy with oxygen when it's not indicated.
And of course, the ones who are needed also need to be treated appropriately. So I think both of those things have an impact on quality of life.
[Susan Jacobs] (20:29 - 22:44)
And the guidelines do recommend regular follow-up assessment. So it's a very important point you make, especially hospitals discharge patients who, typically with their firm exacerbation, that are going to improve. But to Dr. Andrani's point as well, you know, I talked to a lot of clinics across the nation, and especially in ILD. And some have some very interesting and effective built-in follow-up. For example, any patient who gets a new oxygen order, a nurse, and it could be, you know, a nurse or RTMA somebody calls them two weeks later. It's a routine pre-scheduled.
Did you get the equipment? What did you get? How are you using it?
You know, are there problems? And just that two week or whatever, you know, soon intervention can make a huge difference in compliance to that therapy. You know, I can't use my concentrator because I had one.
It's so noisy, my renter upstairs is threatening to move out. Well, we need to address that with this patient. Or I have 20 stairs and they dropped off an e-tank with a trolley and I can't get it out of the house.
So that follow-up for many reasons. And financially, the last thing we need is to be spending money unnecessarily on a patient who doesn't need oxygen anymore. So you raise a very good point.
Yeah, that follow-up, you know, and at clinic we say to patient, bring the equipment you were given. Always bring it with you to clinic so we can check what you're using, how you're using it. And then a whole other conversation around post dose and continuous flow, which, again, you can catch that if you call the patient.
Well, I'm getting six liters a minute. You know, it's on the setting of six. But, you know, my saturations are still 86%.
Well, you're not getting six liters. It's a setting of six. Again, a lot of education follow-up.
And I will tell you our biggest challenge and I'm very involved with the ATS and we have an oxygen group disseminating the outstanding resources we already have. We have online videos, tapes, pictures, handouts, different languages. And we just challenge our challenge getting that out to patients.
And the next is very challenging.
[Tralisa Willis] (22:44 - 23:01)
Susan, you spoke about RTS and nurse practitioners and nurses doing that follow-up, you know, performing that intervention. Are there any other important roles that varied clinicians such as nurses, nurse practitioners and RTS play in LTLT?
[Susan Jacobs] (23:01 - 25:18)
Well, I'm pretty biased on that. You know, yes. So, but it depends on the setting.
You know, I'm from an academic setting, which by the way, full disclosure, I did retire from Stanford a few months ago. So I am no longer in that setting. But I spent my career in many different settings.
Pulmonary rehab, critical care, education, but the last 28 years really looking over clinical trials and seeing a lot of ILD patients. In our setting, the nurses were the ones putting in the orders. They go electronically through a portal.
It's the nurses getting the calls. It's the MA's getting the calls. In some places, if you're so lucky, I've met a couple of RTS who were solely the oxygen person.
All the orders went through one person. And this RT dealt with all the follow-up. She had a set call every week with a local large DME to review all the orders that went in.
And were there issues? So, I mean, that's pie in the sky to me. You know, go out in the community.
They're seeing 30 patients in a day, 20 minutes of visit. It's a different setting. The follow-up is going to be different.
They may not have a nurse in the clinic. So, the MA is the one taking all these calls, dealing with patient education. But at least they can, you know, we're trying to embed, like in the after-visit summary, it's the word oxygen order is in there.
It automatically pens or addends, attaches, educational material. Here's your bill of rights. Here's how oxygen works.
These are the different devices. Who to call? So, there's things we can embed and it takes all these personnel.
But it varies in the setting. Rural communities, a whole different challenge. Non-English speaking patients.
But again, there are resources online in multiple languages. And many of these foundations, COPD, PFF, American Lung, PHA, offer these things. So, it's getting them attached, but it takes, you know, it takes the village.
So, whatever, all those insulate personnel are critical, very critical. And some have the luxury of having a nurse and someone dedicated and others are really barely staffed, you know. Reality is there.
[Tralisa Willis] (25:18 - 25:28)
Dr. Dan Jade, are younger physicians receiving enough education and practical training regarding LTOT initiation, follow-up, and optimization?
[Joao de Andrade] (25:28 - 26:27)
No, absolutely not. I think reflecting, you know, in a previous life, I was a program director. I think while we did talk about oxygen therapy, now I realize, knowing what I know, that we did not impart them the fact that this is an area that needs investigation, that you could take your career and spend 30 years studying it.
And the Susan's point earlier, that physicians do not know the difference between constant flow and pulse flow. There's the assumption that's the same. And that's a failure of us in academic medical centers, right?
So, I take that as a mea cupa. So, we need to really make sure the curriculum around that. The limitations of oxygen therapy, what's the equipment can do and cannot do, so they can be more effective educators that are patients, and then educators to the team that they need to have around them supporting those patients.
Those are all tasks that they will be called to take upon when they leave their training. And we are currently not doing.
[Tralisa Willis] (26:28 - 26:35)
Susan, in your experience, are clinicians fully aware of which patients derive proven benefits from LTLT and which do not?
[Susan Jacobs] (26:35 - 29:01)
Well, I don't think it's a scientific and clinical clinician community. We're aware of those perfect things, but first of all, is assessing benefit. So, you may not know upfront who may benefit or not until you prescribe that oxygen.
A lot of it's also upfront managing the expectations. Many patients think it's going to remove their breathlessness, you know, lots of things. So, an answer to your question, the best we can do is to prescribe it, manage expectations, educate them, and then assess benefit.
And benefit can be defined many different ways. The patient returns. Hey, are you using it?
But then is there less dyspnea, less fatigue? Are you leaving the house more often? Are you able to walk your dog, take out the garbage?
Remember, it's very patient-centric. Are you less anxious? And then physiologically, you know, if there's someone with some pulmonary hypertension, is there echo?
Are there PA pressures? I mean, that's getting a bit invasive. But, you know, physiologically, are they getting benefit?
That's one way to know if some of our LTLT patients have less cough. And then you have to see the other side. Are they so stigmatized that they're not leaving the house?
And they can't carry the equipment. So, have you, in fact, increase their isolation? So, the assessment of benefit, which was follow-up, right?
You have to see them back in three months, six, whatever, or a phone call. Tell them, Edelson, is critical to determine if that patient's using it and if they're experiencing benefit. So, we've had these conversations and there was a publication about the, you know, patient-centric.
If that patient was borderline, they hit that 88%, which means they qualify for payer coverage, but they're telling you there's no benefit and it's a burden. Maybe that patient, you say, you know, let's stop, but we'll reassess you in three to six months. And if they're an IPF patient, you know they're going to change.
If they're a COPD patient, they may have a more stable trajectory, slower progressing. So, it's a very individualized assessment of benefit. But you're right, we don't know the benefits that are going to be experienced by that patient.
You know, some patients grab great benefit report. They just, now they can really get out. Others, it's very different.
So, we need more research.
[Joao de Andrade] (29:02 - 30:15)
I think you spot on, Susan. I think when there's a difference between qualifying for oxygen as defined by our health care system, we as a society, as a health care system, we said, we'll pay for oxygen therapy if XYZ are present. There's a different conversation on whether that particular patient in front of you will benefit from that.
For some patients, now patients with COPD and resting hypoxemia, we can quote research saying, if you use as many hours a day, it's 15 hours a day, your life will be prolonged. All the other populations that we prescribe oxygen for, we cannot provide them that level of evidence and counseling. So, we have to learn to individualize.
You cannot, you can't be, for the patient that Susan gave the example, to 88% for a person that actually study oxygen therapy, although you qualify for, quote unquote, you may actually reduce your quality of life. For somebody else at the same level of hypoxemia, you may improve your quality of life, we have to be able to get those nuanced conversations until we have the evidence to inform what we do.
[Dr. Sanjay Sethi] (30:15 - 30:57)
And that's what's missing in the research. We don't know what parameters to use. I mean, you can individualize it, but wouldn't it be nice if we had a somewhat standard described way of evaluating the benefit, you know, and showing which is responsive and which is, you know, what works.
And, you know, the studies you say, if you use St. George's, you can't do a St. George's respiratory questioning clinic, you know, you need other tools which are manageable within about five minutes of your visit, can you do a proper assessment of benefit and then make a decision? We can't do that today, based on the evidence we have and the guidelines we have. Again, I think in the academic setting, we spend time on all these things and we can, you know, hopefully do a better job, but in the community settings, when they're rushed, it may not be possible.
[Susan Jacobs] (30:57 - 31:23)
And, you know, internationally, it varies in some countries, in order to get oxygen with exertion, you do a blinded walk. So you're blinded and the patients might double-blind it. And I shouldn't say that, but anyway, the patient's blinded for certain.
And if that walk, either distance or breathlessness doesn't improve on the oxygen test, then you don't qualify, even though, you know, so it's a different approach, country by country.
[Dr. Sanjay Sethi] (31:23 - 32:00)
I'm pretty sure that when the one trial that we have, the lot trial looking at ambulatory desaturation, I mean, did they even use portable oxygen concentrators on those patients or was it mostly e-tanks? I mean, I can imagine if you're trying to measure steps, yeah, if you're trying to measure steps as an outcome, if you were, and then you have a, you're dragging a tank behind you, that changes things quite dramatically. So I also think that a lot of those things need to be redone to really assess the impact with the appropriate.
So it's not just, I think you need to address both the outcomes, the outcome measurement and the delivery systems.
[Joao de Andrade] (32:00 - 32:52)
The current equipment that we have may be a hindrance on assessing efficacy of therapy, because if you give someone a new therapy, what all clinical trials we want to see is adherence, right? So if you don't adhere to therapy, we look at the clinical trials, gee, I don't really trust the results of it. It's not enough exposure to the drug, right?
So patients are given an e-tank and that hinders their mobility. And it's one more thing that as they have to deal with their chronic illness, a dearest probably will suffer. And the more current clinical trials, recent clinical trials that largely failed in patients with modern hypoxemia, the level of adherence was not rigorously assessed.
So it was really all self-reporting. And the majority of patients were on e-tanks. So I think you're on to something there.
[Tralisa Willis] (32:52 - 33:16)
You all have actually naturally taken us into our next segment. And we're going to discuss a bit more about research and evidence gaps. You've started this conversation a bit.
And so I just want to ask a question. I'll start with you, Dr. Sethi. Where do you think future research should focus?
Would that be patient selection, technologies, adherence, monitoring, outcomes, all of the things that you're talking about?
[Dr. Sanjay Sethi] (33:16 - 33:52)
To me, the most important thing is what outcomes to look at and how to look at those outcomes and also the whole issue of delivery, not only in terms of the devices, but adequate delivery. Are we really assessing, especially in the context of pulmonary fibrosis? Are we really actually feeding the hypoxemia adequately, especially if it's exertional?
If you're not, then how do you know that it doesn't work? So I think that's an important question that we need to address. So I think I would say those to me, to me, send out, you know, get adequate delivery.
That's the way I would use it. And then adequately assess the outcomes.
[Joao de Andrade] (33:53 - 34:47)
I think would be great if we could find a biomarker, right? Okay. This biomarker in your blood is up.
If you're an oxygen, that's a marker of organ dysfunction. And then we see the biomarker go down if you give patients oxygen therapy. We don't have that yet.
But it's something we need to find. Just to give an example of what's near and dear to my life, which is IPF, part of the building infrastructure for the clinical trials that led to new therapies. We had to, okay, which biomarker we're going to look into.
And then we agreed collectively that FVC was going to be that one. And it has tracked fairly well over time. And now it's an FDA-accepted outcome measure.
We need something similar in oxygen therapy better than what distance, better than dysconia scales, and certainly better mortality, right? Because those studies are tremendously difficult to run.
[Tralisa Willis] (34:47 - 35:00)
Dr. Andrade, just to add to that, what type of new evidence do you believe would be most likely to re-energize interest in LTLT amongst clinicians and Congress organizers?
[Joao de Andrade] (35:00 - 35:19)
I think the equipment, the delivery systems are woefully inadequate. So I think we need to spend some time taking care of that, right? How to deliver the drug in a way that's efficacious?
If we have better delivery systems, we can actually study the drug, which is oxygen, in a better way.
[Dr. Sanjay Sethi] (35:19 - 35:41)
I'm going to reflect on what Susan said. We have a very good delivery system on liquid oxygen, and it's almost impossible to get it. So I think some of the policy aspects need to be addressing that too.
I think that would be if I was to do proper studies, especially in patients with high-flow demands, I would consider doing that. But we can't get it. I mean, it's so difficult.
[Susan Jacobs] (35:42 - 36:59)
Well, I just spent a full day on the Hill in mid-July with the Pulmonary Fibrosis Foundation, and we presented some new data that patients are being kept in the hospital because they can't be discharged home solely because they don't have access to high-flow oxygen. That was a new kind of revelation to us. We did a survey in collaboration with the Pulmonary Hypertension Association, across the nation, got about 52 responses.
This is happening pretty commonly in institutions that a patient's retained was otherwise medically stable. They can't go home because they can't get high-flow. We call it hoteling.
And some are saying in the hospital up to weeks just because they can't be discharged on oxygen. So this was a poster presented at the Pulmonary Hypertension Association. So I don't want to divert, but it's exactly right.
We've gone backwards. I had full access to liquid oxygen when I ran a pulmonary rehab program 20 years ago. That is gone.
So access to high-flow and just device development in general. There is some interesting device attempts at high-flow, low-weight, long-lasting portable, and also auto-titration things. But liquid alone to come back is a very high priority to us.
[Dr. Sanjay Sethi] (36:59 - 37:09)
I mean, we've got auto-tituating insulin pumps. I mean, why can't we have auto-tituating oxygen? I mean, we can.
I mean, there are things out there, but they're not mainstream in any way.
[Tralisa Willis] (37:09 - 37:32)
But we've talked about where long-term oxygen therapy stands today. Let's finish by looking ahead and considering what needs to happen to bring this topic back into sharper focus. I'm just going to ask this question to the entire panel.
If you could change one thing to bring LTLT back into mainstream scientific conversation, what would it be?
[Susan Jacobs] (37:32 - 38:38)
I think we touched on this a little bit, but I think approaching and treating oxygen as a drug. And along with that, I would argue for the need for a national registry. You know, we have some very, very successful registries that have been performed alongside a trial, but with drugs and also just freestanding registries that we've been able to extract endless and effective and meaningful data over time.
Other countries have these registries. I think we're missing an opportunity to be able to do research. So having some type of a national registry, whether it's collaborating with CMS, payers, national oxygen companies, academic research, but I just think that's the only way we have to leverage some data and long-term to see who's using oxygen.
How are they using it? How long are they using it? Are they high flow, low flow?
What's their disease category? And learn about these predictors of who best benefits. I think that would be life-changing, not life-changing me, but research-changing.
Science, it would provide us some data to work with.
[Joao de Andrade] (38:38 - 40:11)
I think we are now in a phase of human history, particularly in this country, where EMRs are lower the place and we have now artificial intelligence that is getting into clinical practice. We are running clinical trials in pragmatic ways, sort of more efficient, more economical. So I think I would like to see a federally funded effort to create a network that would study oxygen therapy to develop high-level questions that could be answered in a pragmatic way, integrating learning EMR systems, creating a national registry.
That is not terribly costly. You just need some startup money. Well, maybe I'm too optimistic.
But I think it would be much more economical now with the tools that we have than 20 years ago. I think we need to try to leverage all the infrastructure for clinical care and research. There are several institutions where, so the concept of the learning EMR, how can we leverage the electronic medical record system to answer questions that are sort of otherwise would require long-term trials to be answered.
So that would be what I would like to see the field. Obviously, as a step one would be return of liquid oxygen so we can actually give it to patients when needed, and then device development that would allow us to properly study and deliver the drug.
[Dr. Sanjay Sethi] (40:11 - 40:45)
I would have to add more technological development. I think there is clearly an improvement, but there is a long way to go. I mean, see how lung cancer screening got revolutionized.
Why? Because we had wonderful CT scanners which put on to the millimeter and then blow those CT scanners and how that completely changed how we look for lung cancer. So here again, in terms of management, I think there was a long, there could be more more emphasis in technological development to deliver better, to measure better, and those kind of things.
So I think there's Apple's cohort.
[Tralisa Willis] (40:45 - 40:59)
Thank you. And I want to pose this question for the group as well. What message would you like respiratory clinicians to take away regarding the ongoing importance of long-term oxygen therapy?
[Joao de Andrade] (40:59 - 41:31)
When one of your patients qualifies for oxygen therapy, pause a little bit and take the time to understand what your patient's goals are and try to align your education and the way you treat their goals and what your goals are as a physician. So treat oxygen therapy as if you would, the way you treat any drug that you prescribe seriously and be mindful of the need to tailor what you're going to do to each patient.
[Dr. Sanjay Sethi] (41:32 - 41:58)
I would add to that that there are both potential benefits and potential burden of oxygen. It's not like prescribing an inhaler or a pill. So yeah, we need to be circumspect about how we prescribe it and in the fall a lot.
And it's expensive. I mean, there's another thing, you know, because we don't see the cost of it. It goes into the DME and we don't see, you know, a lot of these patients have Medicare.
But, you know, it's not, it's not a cheap intervention. It costs money. So we have to be smart about it.
[Susan Jacobs] (41:59 - 43:42)
I think the big priority is matching that patient to the right equipment and approach, as you both have mentioned. Otherwise, I think it's fraught with risk of non-adherence. So who is a patient?
What is their disease? What's their trajectory? Living situation, living alone or not.
High flow, low flow, which means the clinicians have to know the equipment. Although in reality, if they're high flow, it's pretty easy now because they just get an e-tank. I mean, it's, but again, it takes that education.
Matching that patient with the right equipment. And then the follow up. And I think managing expectations from the front can really improve compliance.
Like you mentioned, what are your goals for this therapy? What should they expect from this therapy? And that you're going to reevaluate them in a few months.
So it's really personalized, you know, that you do like, you said, take a minute and think about this. Not just write the order. It's not going to play out well.
So matching these patients, patient-centric approach, you know, they're very different patients across the spectrum. Some are full working, you know, peak of a career. Some are young women with, you know, lamb and rare lung diseases, managing small children.
I mean, you have to think about that patient's needs. Physiologic, sociologic, the whole gamut. It's a very devastating beginning of a treatment for, I would say, 99% of patients.
I haven't heard a patient yet say, you know, thank goodness I finally get on. I mean, it's an occasion if they're really fraught with breathlessness and dyspnea, but that's rare.
[Tralisa Willis] (43:42 - 44:11)
If LTOT has truly lost airtime, today's discussion reminds us why it still deserves a place on Congress stages in clinical practice and in the broader respiratory dialogue. If this episode resonated with you, check out the resources linked in the episode notes and share this episode with someone who needs to hear it. Thank you, our guests, for your time and for your expertise, and thank you, our listeners, for listening to the Lung Health Champion podcast.
[Disclaimer] (44:13 - 45:11)
Thanks for listening to Lung Health Champion. If today's episode helped you breathe a little easier, be sure to leave us a rating or review on Spotify or Apple Podcasts. It'll help the show reach other potential Lung Health Champs.
If you have any questions about today's episode or have suggestions for topics you'd like covered on the show, feel free to reach out to us via email at share@COPDfoundation.org. For more insights on Lung Health, follow us on Instagram and Facebook by clicking the links in the show notes. For more info on what we do at the COPD Foundation, visit our website at COPDfoundation.org.
And don't forget to subscribe or follow the show on your favorite podcast app to make sure you never miss an episode as we continue to empower everyone to breathe easy. This podcast is for educational purposes only and is not a substitute for medical advice. Always consult your health care provider with questions about your care.
Apple Podcasts
Spotify
Amazon Music
YouTube 